Heterosexual transmission of human immunodeficiency virus (HIV) is the most common form of HIV transmission worldwide. Although male condoms, when consistently used, offer protection from sexual transmission, women are often not able to negotiate condom use with all partners [1]. Thus, femalecontrolled methods for HIV and other sexually transmitted disease protection are needed. Nonoxynol-9 (N-9), a nonionic detergent, is the only spermicide approved for use in the United States and has been evaluated for in vitro and in vivo activity against HIV, Chlamydia trachomatis, and Neisseria gonorrhoeae. Several N-9 formulations protect against C. trachomatis and N. gonorrhoeae [2] [3] [4] ; however, the effect on HIV transmission has varied by preparation used and study design [1, [4] [5] [6] . At high concentrations, resultant genital ulcerations may facilitate HIV transmission [4] . In addition, use of N-9 as a contraceptive has been associated with an increased rate of introital colonization with Escherichia coli and of urinary tract infections [7] [8] [9] . Thus, as large-scale studies of the potential protective effects of N-9 use are underway, more detailed evaluation of the effects of various N-9 preparations on vaginal flora and epithelium are necessary. By use of colposcopic examination and quantitative vaginal cultures, we evaluated the effects of three commercially available N-9 products on vaginal flora and epithelium among women after a single use, in the absence of sexual activity, to isolate the effects attributable to N-9 products alone.
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Methods
Healthy female volunteers with regular menstrual cycles were recruited from University of Washington clinics. Enrollment occurred between October 1996 and March 1998. All women were interviewed regarding demographics, medical and sexual history, and current genital symptoms. All had physical examinations that included pelvic examination and specimen collection for vaginal and cervical Gram's stain, quantitative vaginal culture, vaginal pH determination, vaginal wet mount, cervical cultures for N. gonorrhoeae, C. trachomatis, and herpes simplex virus and colposcopic examination of the vagina and cervix.
After baseline examination, a single dose of the N-9 preparation was placed into the vagina without a speculum in place. Preparations studied sequentially in 16 women each included a 5-mL dose of 4% N-9 gel (200 mg; Conceptrol; Advanced Care Products, New Brunswick, NJ), a prepackaged application (1.5 mL) of 3.5% N-9 gel (52.5 mg; Advantage-24; Columbia Laboratories, Miami), and a 28% 2.5-g N-9 vaginal contraceptive film ([VCF] 700 mg; Apothecus, Oyster Bay, NY). After insertion of the preparation, repeat pelvic examinations for collection of specimens as listed above (except cervical cultures for gonorrhea, chlamydia, and herpes) and repeat colposcopic evaluations were done at 30 min and Vaginal smears were Gram's stained and evaluated by use of the criteria described by Nugent et al. [10] . Cervical smears were also examined for the number of polymorphonuclear leukocytes per ϫ1000 field to evaluate for increases in inflammatory cells with N-9 use. For quantitative vaginal culture, two Dacron swabs were saturated with vaginal secretions from the lateral vaginal fornix and placed into an anaerobic transport tube (Port-a-Cul; Becton Dickinson, Cockeysville, MD) for overnight transport (within 24 h) to the research microbiology laboratory at Magee-Womens Hospital, Pittsburgh. This transport device preserves viability of aerobic and anaerobic bacteria in clinical samples up to 24 h [11] . Vaginal swabs were obtained for pH determination and inoculation of saline for microscopic examination for clue cells, hyphal forms, and motile trichomonads. At the baseline visit only, Dacron swabs were obtained from the cervix for inoculation of modified Thayer-Martin agar for isolation of N. gonorrhoeae, McCoy cell monolayers for detection of C. trachomatis, and human diploid fibroblasts for identification of herpes simplex virus and were processed as elsewhere described [12, 13] .
Laboratory personnel were blinded to the N-9 preparation but not to the subject visit sequence. Vaginal swabs for culture were removed from the transport gel within a biologic safety cabinet, placed into 1.5 mL of prereduced balanced salt solution, and vortexed. The resultant 1:10 dilution of vaginal fluid was then used to prepare serial 1:10 dilutions (10 1 -10 7 ) with sterile prereduced saline [14] . A 100-mL volume of the original suspension and of each of the dilutions was inoculated onto prereduced brucella agar supplemented with 5% sheep blood, vitamin K, and hemin (Prepared Media Laboratories [PML], Tualatin, OR) and onto Columbia agar supplemented with 5% sheep blood (PML), two plates of human blood bilayer Tween (HBT) agar (Becton Dickinson), and one plate of prereduced laked blood kanamycin agar (PML). In addition, 1 Ragosa and 1 chocolate agar plate were inoculated with 100 mL of the initial undiluted vaginal fluid suspension. The Columbia agar, one set of HBT plates, and the chocolate agar were incubated at 36ЊC in 5%-7% CO 2 for у48 h; the rest were incubated within an anaerobic chamber (Bactron IV; Shel Lab, Cornelius, OR) at 36ЊC for у5 days. Bacteria were identified by gas chromatography, biochemical tests, and sugar fermentation patterns, as elsewhere described [15] .
All lactobacilli were tested for production of H 2 O 2 in a qualitative assay on tetramethylbenzidine agar plates (prepared in house) [16] . For isolation of genital mycoplasmas, the prereduced saline solution and each of the dilutions were inoculated with a 0.01-mL silver calibrated loop onto the surface of an A7B plate prepared in house, and the plate was incubated at 36ЊC in 5%-7% CO 2 for a minimum of 72 h [14] . In addition, 100 mL of the prereduced solution was used to inoculate broth prepared on site for the isolation of Ureaplasma urealyticum and Mycoplasma hominis. Broth was incubated at 36ЊC for 48 h, and then subcultured. Mycoplasmas were identified by their characteristic morphology on the agar plate.
Colposcopy was performed at each visit to examine the vaginal and cervical mucosa at ϫ10-ϫ40 magnification. A modified WHO colposcopy scoring chart was used to assess for erythema, edema, exudate, petechial hemorrhage, nodules, and epithelial disruption.
For evaluation of changes in vaginal bacterial flora over time, infrequent isolates, including group B streptococci, Staphylococcus aureus, U. urealyticum, and M. hominis, were excluded from further analyses. U. urealyticum was present at baseline in 5, 2, and 1 women, for the three formulations, 4% gel, 3.5% gel, and 28% film, respectively. M. hominis was present in 0, 0, and 1 woman for the three formulations. Species belonging to the genera Bacteroides, Porphyromonas, and Prevotella were grouped together as anaerobic gram-negative rods, for ease of presentation. To assess changes over time, we graphed the median log concentration of a microorganism among women positive for the species for each time point for a given preparation. Changes in the median log concentration of a species over time for a given N-9 formulation were assessed by use of Friedman's test for K-related samples [17] . All women positive for a species at any sampling time were included. To compare the proportion of women positive for a given species at each time point for a given formulation, frequency of isolation was compared by Cochran's Q test [18] . To compare changes between the groups receiving different N-9 formulations, the median log concentration of a given species was compared at each time point for each formulation by use of the Kruskal-Wallis test for K independent samples [17] .
Results
Demographic and behavioral characteristics of the women enrolled in each group are shown in table 1. Most were young, single, and nulligravida. There were no significant differences at enrollment, although the women in the N-9 film group tended to smoke more than those in other groups (x 2 for trend, P ϭ ). Contraceptive use among the women who were sexually .09 active was similar between groups. The majority had normal vaginal flora by Gram's stain at enrollment. All women tested negative for N. gonorrhoeae, C. trachomatis, and Trichomonas vaginalis at enrollment. Figures 1-6 show the median log concentration and proportion of women positive at each sampling interval, for the three N-9 formulations. Concentrations of H 2 O 2 ϩ and H 2 O 2 Ϫ lactobacilli dropped significantly at 30 min (except H 2 O 2 Ϫ lactobacilli with 4% N-9) and 4 h with all three N-9 formulations but returned to baseline levels by 24 h (figures 1, 2 ). There were no significant differences in the decreased lactobacilli concentrations between N-9 groups (H 2
The concentration of G. vaginalis dropped transiently in all three groups but returned to baseline levels in all groups by 24-48 h ( figure 3 ). The number of women positive for G. vaginalis decreased significantly at 0.5, 4, and 24 h in each group, although less dramatically in the 3.5% gel group. The concentration of E. coli increased within each N-9 group, with the greatest change occurring in the 4% gel recipients (figure 4). The number of women with E. coli detected increased significantly in the 4% gel group but not in the other two groups. Enterococcus levels increased over time in each group (P ϭ ), but no differences between N-9 groups were observed .03 ( ; figure 5) . No significant changes in the number of P 1 20 women with enterococci were observed in any group. Concentrations of nonpigmented anaerobic gram-negative rods initially decreased at 0.5 and 4 h, then increased slightly in each group, primarily at and у24 h ( figure 6 ). The number of women with these bacteria isolated decreased significantly at 0.5 and 4 h, then returned to the baseline frequency. Table 2 summarizes symptoms and physical and colposcopic examination findings. Vulvar itching or pain/burning and abnormal discharge were the most frequent complaints and occurred most frequently with the 28% film. Vulvar itching or burning occurred in 2 women (13%) receiving 4% N-9 gel, in 1 (6%) receiving 3.5% N-9 gel, and in 2 (13%) receiving the 28% film. Vaginal pain or burning was reported by 4 women (25%) receiving the 28% film but only 1 subject, at one visit, in the other two groups. The majority of vulvar and vaginal symptoms resolved by 48 h after insertion of each product. Abnormal discharge was reported by 2 (13%) of those in the 4% gel group, 1 (6%) in the 3.5% gel group, and 7 (44%) in the 28% film group ( , x 2 test). Physical examination of P ϭ .02 the vulva, vagina, and cervix showed no increase in abnormalities over baseline findings in the three groups, except for an increase in the proportion of women with abnormal cervical mucous at 24-72 h after insertion of the 28% film. This change in cervical mucous was not necessarily related to an increase in cervical white blood cell count, since similar slight increases in cervical white blood cell counts were seen on Gram's stain, beginning 4 h after N-9 insertion in all three groups.
Changes from the baseline findings of colposcopic examination were infrequent in all three groups. In the 4% gel group, 4 subjects (25%) had exudate at 4 h, probably related to persistence of the gel. Two subjects in the 3.5% gel group had transient edema of the cervix, and 1 subject (6%) in this group developed new epithelial disruption at 24 h that resolved by 48 h. Two subjects in the 28% film group had transient vaginal and cervical erythema, and 1 (6%) developed transient epithelial disruption.
Discussion
The results of this study suggest that the use of N-9 intravaginally results in transient reductions in the concentrations of H 2 O 2 -producing lactobacilli, with restoration to preuse levels in 24 h. The decreased concentrations of lactobacilli at 30 min and 4 h after N-9 insertion are consistent with previous in vitro studies showing inhibition of lactobacilli growth at low concentrations of N-9 (4%-16%) [19, 20] . These studies suggested greater susceptibility of H 2 O 2 ϩ lactobacilli than of H 2 O 2 Ϫ strains [21] . This differential effect suggested by in vitro studies was not confirmed in the current study. N-9 concentrations locally in the vagina may have been high enough to produce similar inhibition or dilution of both H 2 O 2 ϩ and H 2 O 2 Ϫ strains. Lactobacilli concentrations rebounded to pretreatment levels by 24 h, but chronic inhibition, with loss of vaginal lactobacilli, could result from repeated use of vaginal N-9 products, a condition not evaluated in the present study. However, in a recent study of women using the same 3.5% N-9 gel as that used in the current study (daily use for 2 weeks), loss of H 2 O 2 ϩ lactobacilli was not observed [22] . Only 23% of women in that study had H 2 O 2 ϩ lactobacilli at baseline, versus 160% in the current study, suggesting a high rate of abnormal flora before N-9 use. Women colonized only with H 2 O 2 Ϫ lactobacilli did lose colonization, however. Sampling was infrequent in that study, allowing for rebound of bacteria between sampling.
Lack of H 2 O 2 ϩ lactobacilli has been associated with a 4-fold increased risk of acquisition of bacterial vaginosis, compared with that for women with H 2 O 2 ϩ lactobacilli [23] . In turn, bacterial vaginosis has been associated with multiple complications, including pelvic inflammatory disease [24] ; postabortal [25] and postsurgical infections [26, 27] ; and, most recently, an increased risk of HIV seroconversion [28] . Although the observed inhibition of Gardnerella vaginalis is also consistent with previous in vitro studies [20] , longitudinal studies have not shown routine N-9 use to decrease acquisition of bacterial vaginosis [29] .
Of concern is the number of women with increased vaginal concentration of E. coli after N-9 use, which persisted up to 48 h. These observations are consistent with multiple previous studies both in vivo and in vitro. Women who use a diaphragm with N-9 spermicide have a 2.0-to 3.5-fold increased risk for urinary tract infection, compared with sexually active women not using a diaphragm or spermicide [7, 30] . Subsequently, similar increased rates of bacteriuria or urinary tract infection have (6) 1 (6) 1 (6) 1 (6) 1 (6) 0 1 (6) 1 (6) 1 (6) 1 (6) (6) 2 (13) been shown among women using N-9 contraceptive formulations, including those using only N-9-coated condoms [8, 9, 31] . A recent study also showed increased E. coli colonization of the vagina after N-9 insertion in the absence of sexual activity or diaphragm use [32] . In vitro studies have shown both decreased susceptibility of E. coli to N-9, especially fimbriated strains, compared with lactobacilli susceptibility and increased adherence of E. coli to vaginal epithelial cells in the presence of N-9 [20] . Thus, the current study confirms previous epidemiologic and laboratory studies suggesting increased levels and rates of E. coli colonization of the vagina after N-9 use. Since these effects persisted up to 48 h, the effect would be expected to be magnified with repeated use. This increased E. coli colonization could lead to increased rates of urinary tract infection. Symptoms were infrequent after use of the three preparations in this study, although 25% of women using the 28% vaginal film reported vaginal pain or burning. Thus, women are unlikely to discontinue use of low-dose N-9 products because of side effects. Likewise, gross-examination findings were minimal after N-9 use. No increased rate of epithelial disruption over baseline was observed, which is consistent with a previous study of use of Advantage 24 gel [33] . Increased rates of vaginal ulceration have been reported with the use of the vaginal contraceptive sponge, which contains levels of N-9 higher than those used in any of the formulations in the current study [4] .
In summary, single doses of the three N-9 preparations studied were well tolerated by participants. However, the transient decreased concentrations of lactobacilli and increased levels of E. coli seen with all three preparations are of concern and likely are intensified and perpetuated with repeated use of N-9 as a microbicide. It is unclear from the present data whether the transient decreased concentrations of lactobacilli are related to the subsequent increase in vaginal E. coli or whether these are independent events. Nevertheless, with chronic use, the changes in flora may lead to urinary tract infection and resultant complications. Development of vaginal microbicides for femalecontrolled methods of protection against HIV and other sexually transmitted diseases without negative effects on the vaginal flora and without spermicidal activity is crucial.
